(Q36040871)

11 August 2017

1 reference

title

Thalidomide and immunomodulatory drugs in the treatment of cancer (English)

1 reference

11 August 2017

0 references

Athanasios Dimopoulos

object named as

Meletios A Dimopoulos

series ordinal

2

0 references

author name string

Aristotle Bamias

series ordinal

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

Expert Opinion on Investigational Drugs

11 August 2017

published in

1 reference

11 August 2017

volume

14

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

45-55

1 reference

Thalidomide is an inhibitor of angiogenesis

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide: emerging role in cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide for patients with recurrent lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide can costimulate or suppress CD4+ cells' ability to incorporate [H3]-thymidine--dependence on the primary stimulant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide in multiple myeloma: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide as initial therapy for early-stage myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Treatment of Waldenstrom's macroglobulinemia with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide treatment in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Efficacy and safety of thalidomide in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

The treatment of advanced renal cell cancer with high-dose oral thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Phase II trial of thalidomide in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Low-dose thalidomide treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide in patients with cachexia due to terminal cancer: preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide-induced neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Treatment of plasma cell dyscrasias with thalidomide and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

Activity of thalidomide in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.45

21 January 2018

Identifiers

DOI

10.1517/13543784.14.1.45

1 reference

11 August 2017

1 reference